Home
Resources
Diseases
Training
SYSVAC
About
Registry
E-learning courses
News
Events
Network
Vision and Mission
Steering Committee
Map
Meetings
Join us
Home
Resources
Resources
Selected
SAGE documentation
2015
2012
Clear all
Type of publications
Guidelines
(1)
NITAG documentation
(124)
Reports
(16)
SAGE documentation
(43)
Scientific publications
(19)
Systematic reviews (SYSVAC)
(153)
Topics
Evidence to recommendation table
(1)
GRADE table
(31)
Position paper
(9)
SAGE background document
(1)
Regions
Countries
Diseases
Hepatitis A
(6)
Human papillomavirus (HPV)
(2)
Influenza
(12)
Japanese encephalitis
(10)
Malaria
(1)
Meningococcal disease
(5)
Pertussis
(4)
Pneumococcal disease
(1)
Publication date
2015
(24)
2012
(19)
2024
(1)
2023
(2)
2022
(35)
2021
(6)
2020
(8)
2019
(2)
2018
(21)
2017
(45)
2016
(3)
2014
(4)
2013
(7)
2011
(3)
2010
(2)
2009
(2)
2008
(3)
2007
(1)
2006
(2)
2004
(1)
Target population
Children
(1)
Healthcare workers
(2)
Newborn
(3)
Older adults
(1)
Pregnant women
(1)
Risk group
(2)
Available to download in languages
English (EN)
(43)
French (FR)
(10)
43 results found
2015
∙
WHO
Meningococcal A conjugate vaccine: updated guidance
2015
∙
SAGE
Safety of pertussis vaccines in immunocompetent infants and children
2015
∙
SAGE
Duration of protection conferred by MenA conjugate vaccination in immunocompetent children (3 to 24 months of age) against serogroup A meningococcal disease
2015
∙
SAGE
Efficacy of a single-dose MenA conjugate vaccination in immunocompetent children (9 to 24 months of age) against serogroup A meningococcal disease
2015
∙
SAGE
Efficacy of a two dose schedule of MenA conjugate vaccination in immunocompetent children (3 to 9 months of age) against serogroup A meningococcal disease
2015
Mosquirix: Opinion on medicine for use outside EU
2015
∙
SAGE
Pertussis Vaccine Evidence to Recommendations Table
2015
∙
SAGE
Protective Efficacy/Effectiveness of Whole Cell Pertussis Vaccines (wP) in Immunocompetent Infants and Children
2015
∙
SAGE
Safety of MenA conjugate vaccination in immunocompetent children (3 to 24 months of age)
2015
∙
SAGE
What is the risk of serious adverse events following vaccination with live attenuated JE vaccine?
Home
Resources
Diseases
Training
SYSVAC
News
Events
Network
Sign in / Register